Enhanced HIV-1 specific immune response by CpG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the Trimera murine model of HIV-1 infection

被引:10
作者
Ayash-Rashkovsky, M
Borkow, G
Davis, HL
Moss, RB
Bartholomew, R
Bentwich, Z
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
[2] Coley Pharmaceut Grp, Ottawa, ON K2K 3A2, Canada
[3] Immune Response Corp, San Diego, CA USA
关键词
vaccines; cytosine-phosphate-guanosine oligonucleotides; small animal model;
D O I
10.1096/fj.04-3185fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have recently developed a novel small animal model for HIV-1 infection (Ayash-Rashkovsky et al., http://www.fasebi.org/cgi/doi/10.1096/fj.04-3184fje; doi:10.1096/fj.043184fie). The mice were successfully infected with HIV-1 for 4-6 wk with different clades of either T- or M-tropic isolates. HIV-1 infection was accompanied by rapid loss of human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell activation. HIV specific human Immoral and cellular immune responses were observed in all HIV-1 infected animals. In the present study, HIV specific human immune responses, both Immoral and cellular, were generated in noninfected Trimera mice, after their immunization with gp120-depleted HIV-1 antigen, presented by autologous human dendritic cells. Addition of CpG ODN to the antigen-pulsed DCs significantly enhanced (by 2- to 30-fold) the Immoral and cellular HIV-1 specific immune responses. Only mice immunized with the HIV-1 immunogen and CpG were completely protected from infection with HIV-1 after challenge with high infection titers of the virus. This novel small animal model for HIV-1 infection may thus serve as an attractive platform for rapid testing of candidate HIV-1 vaccines and of adjuvants and may shorten the time needed for the development and final assessment of protective HIV-1 vaccines in human trials.
引用
收藏
页码:1152 / +
页数:19
相关论文
共 60 条
[1]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[2]  
2-U
[3]   Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via imunostimulatory oligonucleotides - relevance to AIDS vaccines in developing countries [J].
Ayash-Rashkovsky, M ;
Weisman, Z ;
Diveley, J ;
Moss, RB ;
Bentwich, Z ;
Borkow, G .
VACCINE, 2002, 20 (21-22) :2684-2692
[4]   Induction of antigen-specific Th1-biased immune responses by plasmid DNA in Schistosoma-infected mice with a preexistent dominant Th2 immune profile [J].
Ayash-Rashkovsky, M ;
Weisman, Z ;
Zlotnikov, S ;
Raz, E ;
Bentwich, Z ;
Borkow, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (05) :1169-1176
[5]   Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection [J].
Ben-Yedidia, T ;
Marcus, H ;
Reisner, Y ;
Arnon, R .
INTERNATIONAL IMMUNOLOGY, 1999, 11 (07) :1043-1051
[6]   Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood [J].
Bender, A ;
Sapp, M ;
Schuler, G ;
Steinman, RM ;
Bhardwaj, N .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 196 (02) :121-135
[7]   Immune dysregulation in Ethiopian immigrants in Israel: Relevance to helminth infections? [J].
Bentwich, Z ;
Weisman, Z ;
Moroz, C ;
BarYehuda, S ;
Kalinkovich, A .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 103 (02) :239-243
[8]   CpG-A-induced monocyte IFN-γ-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-α [J].
Blackwell, SE ;
Krieg, AM .
JOURNAL OF IMMUNOLOGY, 2003, 170 (08) :4061-4068
[9]  
Böcher WO, 2001, EUR J IMMUNOL, V31, P2071, DOI 10.1002/1521-4141(200107)31:7<2071::AID-IMMU2071>3.0.CO
[10]  
2-D